Alkeon Capital Management LLC Sells 150,000 Shares of Astera Labs, Inc. $ALAB

Alkeon Capital Management LLC lessened its stake in Astera Labs, Inc. (NASDAQ:ALAB) by 37.5% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 250,000 shares of the company’s stock after selling 150,000 shares during the quarter. Alkeon Capital Management LLC owned 0.15% of Astera Labs worth $48,950,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Clearstead Advisors LLC raised its holdings in shares of Astera Labs by 13.6% during the third quarter. Clearstead Advisors LLC now owns 636 shares of the company’s stock worth $125,000 after acquiring an additional 76 shares during the period. Great Valley Advisor Group Inc. boosted its stake in Astera Labs by 2.2% in the 2nd quarter. Great Valley Advisor Group Inc. now owns 4,119 shares of the company’s stock worth $372,000 after purchasing an additional 90 shares during the period. Rye Brook Capital LLC increased its holdings in Astera Labs by 1.1% during the 3rd quarter. Rye Brook Capital LLC now owns 9,200 shares of the company’s stock worth $1,801,000 after purchasing an additional 100 shares in the last quarter. Assetmark Inc. increased its holdings in Astera Labs by 374.1% during the 3rd quarter. Assetmark Inc. now owns 128 shares of the company’s stock worth $25,000 after purchasing an additional 101 shares in the last quarter. Finally, SlateStone Wealth LLC raised its stake in shares of Astera Labs by 1.3% in the 3rd quarter. SlateStone Wealth LLC now owns 12,744 shares of the company’s stock valued at $2,495,000 after purchasing an additional 160 shares during the period. Institutional investors own 60.47% of the company’s stock.

Astera Labs Price Performance

Shares of ALAB opened at $120.31 on Friday. The firm has a 50-day moving average of $147.89 and a 200-day moving average of $168.11. Astera Labs, Inc. has a one year low of $47.13 and a one year high of $262.90. The company has a market cap of $20.48 billion, a PE ratio of 98.61, a price-to-earnings-growth ratio of 2.37 and a beta of 1.74.

Astera Labs (NASDAQ:ALAB) last released its quarterly earnings data on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, topping the consensus estimate of $0.51 by $0.07. Astera Labs had a net margin of 25.70% and a return on equity of 16.12%. The company had revenue of $270.58 million for the quarter, compared to analyst estimates of $249.46 million. During the same period in the previous year, the business earned $0.37 EPS. Astera Labs’s revenue for the quarter was up 91.8% compared to the same quarter last year. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. Analysts expect that Astera Labs, Inc. will post 0.34 earnings per share for the current year.

Insider Activity

In other news, General Counsel Philip Mazzara sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $117.47, for a total value of $1,174,700.00. Following the completion of the sale, the general counsel directly owned 128,084 shares of the company’s stock, valued at $15,046,027.48. This trade represents a 7.24% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Michael Truett Tate sold 12,001 shares of Astera Labs stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $123.81, for a total value of $1,485,843.81. Following the transaction, the chief financial officer owned 192,083 shares of the company’s stock, valued at $23,781,796.23. This represents a 5.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 224,292 shares of company stock valued at $27,676,069. 12.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of brokerages have recently commented on ALAB. BNP Paribas Exane began coverage on Astera Labs in a report on Thursday, November 20th. They issued an “outperform” rating on the stock. Morgan Stanley reissued an “overweight” rating and issued a $210.00 target price on shares of Astera Labs in a research report on Wednesday, December 3rd. Royal Bank Of Canada assumed coverage on Astera Labs in a research note on Wednesday, January 14th. They issued an “outperform” rating and a $225.00 target price on the stock. Weiss Ratings cut shares of Astera Labs from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, February 23rd. Finally, Barclays set a $165.00 price objective on shares of Astera Labs in a report on Thursday, January 15th. Fifteen investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $202.22.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.